Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.
Level 5 - mechanism / opinion, no new human data
Editorial commentary on a companion study with no new empirical data.
PubMed 15237100 · doi:10.1038/sj.bjp.0705832
What was done
This paper is an editorial commentary discussing a companion study by Chang et al. on the role of the Maillard reaction in age-related cardiovascular stiffness and the use of aminoguanidine to inhibit nonenzymatic protein crosslinking in the myocardium and arterial walls.
What was found
The abstract presents no quantitative data or specific numerical endpoints. It summarizes qualitatively that aminoguanidine retards the age-related decline in the elastic properties of the left ventricle and arteries.
Why it matters
Targeting nonenzymatic collagen crosslinking offers a mechanistic approach to preventing arterial and myocardial stiffness, which underlie age-related isolated systolic hypertension and diastolic heart failure.
Limits
The record is a brief commentary containing no primary data, sample size, or quantitative metrics. Specific details regarding experimental design, species model, and translational safety are absent from the abstract.
Cited by
- supports Elevated blood glucose reacts with collagen in blood vessels and the myocardium via the Maillard reaction (glycation), leading to tissue cross-linking and vascular/cardiac stiffness.